The European Parliament has voted overwhelmingly to adopt legislation that is supposed to transform the way medicines are brought to market and accessed across much of Europe. But the effort — which must still be approved by the European Council — drew mixed reactions from the pharmaceutical industry and consumer groups.
A key sticking point concerns data protection. This refers to the period of time in which a generic company cannot use study data generated by brand-name manufacturers to win regulatory approval to sell a medicine. The issue is seen as crucial because drug companies want as much protection as possible to extend sales, while advocacy groups argue that added protection costs consumers more money.
The parliament voted in favor of dropping data protection slightly to seven-and-a-half years from the existing eight-year period. Drug companies would be eligible for 12 months of additional data protection if their medicine addresses an unmet medical need, six more months if comparative clinical trials are conducted, and yet another six months if a significant share of R&D work takes place in Europe.
Click this link for the original source of this article.
Author: Ed Silverman
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.